propranolol has been researched along with Cystic Fibrosis in 5 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Cystic Fibrosis: An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The benefits with bedaquiline or Sirturo® are its ability to likely provide clinically relevant activity as part of multi-drug regimens against tuberculosis (TB) based on clinical data in multi-drug resistant tuberculosis (MDR TB) patients, who were defined as being at least resistant against the two major tuberculostatic medicines (isaoniazide and rifampicine)." | 4.90 | [Two news drugs (ivacaftor & bedaquiline), one biomarker (florbetapir) and a re-positioned drug (propranolol) on the market]. ( Monneret, C, 2014) |
| "Transepithelial potential difference (PD) of isolated segments of the secretory coil of both human control and cystic fibrosis (CF) eccrine sweat glands was measured during stimulation with methacholine (MCh) and isoproterenol (ISO) in vitro." | 3.67 | Differing luminal potential difference of cystic fibrosis and control sweat secretory coils in vitro. ( Sato, K, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Monneret, C | 1 |
| Sato, K | 1 |
| Birnbaum, AK | 1 |
| Wotta, DR | 1 |
| Law, PY | 1 |
| Wilcox, GL | 1 |
| Kester, M | 1 |
| Liedtke, CM | 1 |
| Kaliner, M | 1 |
| Wasserman, SI | 1 |
| Austen, KF | 1 |
1 review available for propranolol and Cystic Fibrosis
| Article | Year |
|---|---|
[Two news drugs (ivacaftor & bedaquiline), one biomarker (florbetapir) and a re-positioned drug (propranolol) on the market].
Topics: Adrenergic beta-Antagonists; Adult; Alzheimer Disease; Aminophenols; Aniline Compounds; Antitubercul | 2014 |
4 other studies available for propranolol and Cystic Fibrosis
| Article | Year |
|---|---|
Differing luminal potential difference of cystic fibrosis and control sweat secretory coils in vitro.
Topics: Adult; Cystic Fibrosis; Epithelium; Evoked Potentials; Humans; Isoproterenol; Male; Membrane Potenti | 1984 |
Functional expression of adrenergic and opioid receptors in Xenopus oocytes: interaction between alpha 2- and beta 2-adrenergic receptors.
Topics: Adenylyl Cyclases; Animals; Brimonidine Tartrate; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; | 1995 |
Alpha 1-adrenergic stimulation differentially regulates ether-linked diacylglycerols in airway epithelial cells from normal and cystic fibrosis patients.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adrenergic beta-Agonists; Adrenergic beta-A | 1996 |
Immunologic release of chemical mediators from human nasal polyps.
Topics: Allergens; Anaphylaxis; Butyrates; Carbachol; Chemotaxis; Cholera; Cyclic AMP; Cystic Fibrosis; Depr | 1973 |